Apalutamide Reduces Risk of PSA Progression by 94% in Nonmetastatic CRPC
Apalutamide (Erleada) lowered the risk of PSA progression by 94% in patients with nonmetastatic castration-resistant prostate cancer, according to a posthoc analysis from the phase III SPARTAN trial.
Source: OncLive